Skip to main content
Clinical Trials/IRCT20090117001556N146
IRCT20090117001556N146
Recruiting
Phase 2

Sulforaphane as an adjuvant therapy in children with attention-deficit/hyperactivity disorder (ADHD): A randomized, double-blind, placebo-controlled clinical trial

Tehran University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age between 6\-11 years
  • Diagnosis of ADHD based on DSM5

Exclusion Criteria

  • Age range outside 6\-11 years
  • Diagnosis of a serious disease, or disease requiring surgery, or neurological diseases
  • Diagnosis of a psychiatric disorder and taking neuropsychiatric drugs, except for ADD
  • History of treatment with sulforaphane in the last three months
  • History of treatment with neuroleptic medication in the last six months
  • Weight less than 13\.5 kg
  • Mental retardation
  • A systolic blood pressure greater than 125 or a resting heart rate less than 60 or greater than 115
  • History of allergy to sulforaphane or methylphenidate

Outcomes

Primary Outcomes

Not specified

Similar Trials